Default company panoramic image
Logo

XENOTIDE BIOTECH

Xenotide Biotech discovers and develops new classes of drugs for the treatment of cancer and age related diseases.

  • Stage Product In Development
  • Industry Biotechnology
  • Location Vancouver, WA, USA
  • Currency USD
  • Founded March 2005
  • Website Xenotide.com

Company Summary

Xenotide has discovered new classes of molecules expected to have widespread application in preventing and treating disease. Xenotide will transition its drugs to human clinical trials at which time it will form strategic alliances with pharmaceutical companies to bring its drugs to a customer base that includes patients with cancer, cardiovascular disease, dementia, and osteoarthritis.

Team

  • Default avatar
    Dr. Shayne R. Squires
    CEO

    Doctor Shayne Squires MD co-founded Xenotide Biotech® in March of 2005 and serves as chief executive officer, and lead scientist. Shayne Squires is a physician, board certified in Internal medicine and nuclear medicine. He has extensive years of experience in research. Prior to co-founding Xenotide Biotech ®, he served as Assistant Professor, Department of Radiology, at the University of Massachusetts Medical School.

  • Default avatar
    Suresh Gupta
    VP of Research

    Dr. Suresh Gupta Ph.D. has over 20 years of experience in research and development that include the screening and development of novel therapeutics for the treatment and prevention of various indications. He is an expert in combinatorial screening of biologic pharmaceuticals and has over 20 peer-reviewed publications.

  • Default avatar
    Corey Park
    President

    Corey Park joined Xenotide Biotech® in January of 2012 and serves as President. Corey comes highly qualified with a background in leadership and management, Notre Dame U. Corey specializes in public markets, biz dev, IPO's/DPO's/APO's. Mr. Park has served in leadership positions for 18 years. Accomplished business strategist with experience taking companies public, negotiating and completing mergers, acquisitions and strategic partnerships.

  • Default avatar
    Steven R. Lazar, Esq.
    Patent Attorney

    Mr. Steven R. Lazar joined Xenotide Biotech®‘s team in July of 2007 and brings more than 16 years of experience in the biotech and pharmaceutical industry with expertise in managing intellectual property portfolios involving due diligence, product clearance and reviews, license review and preparation, patent preparation and prosecution, and oversight of outside counsel in interference and opposition matters.

  • Default avatar
    Cindy McClure
    Managing Director

    Cindy McClure co-founded Xenotide Biotech® in March 2005. Cindy McClure comes to Xenotide Biotech® and serves as Managing Director. Ms. McClure has over 25 years experience as a business owner, Artist/Illustrator, logistics coordinator for large scale events and has successfully executed multimillion dollar license and royalty contracts.

Advisors

  • Default avatar
    Steven R. Lazar, Esq.
    Lawyer
    Unconfirmed
    Default avatar
    Dave Saathoff
    Accountant
    Unconfirmed

Previous Investors

  • Default avatar
    Founders
    Unconfirmed